Financial Performance - The company's revenue for Q1 2025 was ¥387,883,698.30, a decrease of 12.50% compared to ¥443,303,887.87 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥53,259,784.78, representing an 84.79% increase in loss compared to a loss of ¥28,821,454.12 in the previous year[4] - The basic and diluted earnings per share were both -¥0.1036, reflecting an 82.39% increase in loss compared to -¥0.0568 in the same period last year[4] - Net profit for the period was a loss of ¥53,745,471.97, compared to a loss of ¥21,682,586.79 in the previous period, indicating a worsening of approximately 147.5%[16] - The company reported a total comprehensive loss of ¥41,836,296.38, compared to a loss of ¥30,734,726.73 in the previous period[16] Cash Flow - The net cash flow from operating activities improved to -¥51,291,981.79, a 64.28% increase compared to -¥143,612,182.50 in the same period last year[4] - Total cash inflow from operating activities decreased to 428,107,002.27 CNY, down from 451,797,344.65 CNY year-over-year[18] - Cash outflow from operating activities decreased to 479,398,984.06 CNY, compared to 595,409,527.15 CNY in the previous period[18] - The net increase in cash and cash equivalents for the current period is -77,316,974.22 CNY, an improvement from -239,639,024.47 CNY in the previous period[18] - The ending balance of cash and cash equivalents is 787,309,260.67 CNY, down from 1,376,357,042.59 CNY in the previous period[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,195,708,595.15, a decrease of 0.77% from ¥5,236,128,052.84 at the end of the previous year[4] - Total liabilities increased marginally to ¥1,258,305,418.76 from ¥1,253,747,330.56[14] - The equity attributable to shareholders decreased by 1.23% to ¥3,308,485,682.12 from ¥3,349,826,403.95 at the end of the previous year[4] - The company's total assets amounted to ¥5,195,708,595.15, slightly down from ¥5,236,128,052.84[14] Shareholder Information - Total number of common shareholders at the end of the reporting period is 42,590[9] - The largest shareholder, Zhuhai Baolian Investment Holding Co., Ltd., holds 13.64% of shares, totaling 70,147,179 shares[9] - The company has a share repurchase account holding 13,696,600 shares, representing 2.66% of the total share capital[9] Operating Costs and Expenses - Total operating costs decreased to ¥443,013,698.68 from ¥482,388,247.21, a reduction of about 8.1% year-over-year[15] - Research and development expenses were ¥44,061,435.78, down from ¥47,231,870.73, reflecting a decrease of approximately 4.6%[15] - The company experienced a 54.68% decrease in financial expenses, which amounted to ¥2,756,037.15 compared to ¥6,081,459.37 in the previous year[7] Impairment and Gains - The company reported a significant increase in credit impairment losses, which rose by 368.32% to -¥4,970,053.18 compared to -¥1,061,254.57 in the previous year[7] - The company recorded a 90.19% increase in asset disposal gains, amounting to ¥1,077,766.10 compared to ¥566,673.46 in the previous year[7] Accounting and Audit - The company has not undergone an audit for the first quarter report[19] - The new accounting standards will be implemented starting from 2025[19]
科华生物(002022) - 2025 Q1 - 季度财报